Olstein Capital Management L.P. Acquires 5,000 Shares of Hologic, Inc. (NASDAQ:HOLX)

Olstein Capital Management L.P. grew its stake in Hologic, Inc. (NASDAQ:HOLX) by 5.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 90,000 shares of the medical equipment provider’s stock after purchasing an additional 5,000 shares during the period. Olstein Capital Management L.P.’s holdings in Hologic were worth $6,488,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Wolff Wiese Magana LLC acquired a new position in Hologic in the third quarter valued at about $25,000. General Partner Inc. acquired a new position in shares of Hologic in the 4th quarter worth approximately $26,000. Groupama Asset Managment grew its position in Hologic by 9.9% during the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 2,999 shares during the last quarter. Sunbelt Securities Inc. acquired a new stake in Hologic during the 2nd quarter valued at $37,000. Finally, First Horizon Advisors Inc. raised its position in Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 134 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on HOLX. Citigroup lowered shares of Hologic from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $95.00 to $85.00 in a research report on Tuesday, October 1st. Raymond James lifted their price objective on Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. Needham & Company LLC restated a “buy” rating and set a $90.00 target price on shares of Hologic in a research report on Monday, January 13th. Morgan Stanley dropped their price target on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Finally, BNP Paribas raised shares of Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Seven research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $88.92.

Insider Activity at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.88% of the stock is owned by insiders.

Hologic Stock Up 0.5 %

Shares of HOLX stock opened at $71.02 on Friday. Hologic, Inc. has a 12-month low of $68.61 and a 12-month high of $84.67. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The firm has a fifty day moving average of $74.01 and a 200-day moving average of $78.25. The company has a market capitalization of $16.03 billion, a price-to-earnings ratio of 21.33, a P/E/G ratio of 2.43 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last released its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.01. The firm had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company’s revenue was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.89 EPS. As a group, equities research analysts predict that Hologic, Inc. will post 4.27 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.